See more : ORIX JREIT Inc. (8954.T) Income Statement Analysis – Financial Results
Complete financial analysis of Polarean Imaging plc (PLLWF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polarean Imaging plc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Looking Glass Labs Ltd. (NFTX.NE) Income Statement Analysis – Financial Results
- DIGITAL PLUS, Inc. (3691.T) Income Statement Analysis – Financial Results
- PT Hetzer Medical Indonesia Tbk (MEDS.JK) Income Statement Analysis – Financial Results
- Ryanair Holdings plc (RY4C.IR) Income Statement Analysis – Financial Results
- RIGHT ON Co., Ltd. (7445.T) Income Statement Analysis – Financial Results
Polarean Imaging plc (PLLWF)
About Polarean Imaging plc
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 890.93K | 1.03M | 1.19M | 1.06M | 2.30M | 2.44M | 1.24M | 880.65K | 902.34K | 965.43K |
| Cost of Revenue | 555.45K | 684.73K | 677.40K | 346.30K | 925.61K | 633.46K | 297.22K | 488.89K | 308.56K | 168.03K |
| Gross Profit | 335.48K | 348.28K | 508.03K | 710.47K | 1.38M | 1.81M | 939.95K | 391.76K | 593.78K | 797.40K |
| Gross Profit Ratio | 37.66% | 33.71% | 42.86% | 67.23% | 59.78% | 74.03% | 75.98% | 44.49% | 65.80% | 82.60% |
| Research & Development | 4.19M | 607.76K | 638.59K | 480.89K | 161.31K | 642.46K | 176.11K | 145.44K | 162.98K | 269.83K |
| General & Administrative | 3.34M | 8.46M | 6.52M | 5.05M | 6.01M | 6.16M | 4.05M | 1.28M | 1.19M | 769.96K |
| Selling & Marketing | 3.56M | 3.31M | 5.56M | 917.78K | 324.79K | 31.77K | 28.75K | 35.24K | 25.39K | 86.41K |
| SG&A | 6.90M | 11.78M | 12.08M | 5.97M | 6.33M | 6.19M | 4.08M | 1.32M | 1.21M | 856.37K |
| Other Expenses | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89M | 14.02M | 14.82M | 7.33M | 7.39M | 7.07M | 4.86M | 1.45M | 1.51M | 869.11K |
| Cost & Expenses | 13.45M | 14.70M | 15.50M | 7.67M | 8.31M | 7.71M | 5.16M | 1.94M | 1.81M | 1.04M |
| Interest Income | 759.00 | 35.05K | 2.59K | 100.77K | 508.00 | 184.00 | 129.00 | 147.00 | 159.31K | 37.69K |
| Interest Expense | 15.99K | 23.76K | 20.74K | 19.73K | 91.68K | 188.06K | 34.06K | 4.32K | 0.00 | 0.00 |
| Depreciation & Amortization | 959.78K | 1.02M | 918.40K | 942.62K | 775.69K | 598.87K | 387.84K | 9.35K | 9.99K | 12.74K |
| EBITDA | -11.19M | -12.78M | -13.38M | -5.73M | -5.26M | -4.64M | -3.55M | -1.05M | -617.40K | -58.97K |
| EBITDA Ratio | -1,256.55% | -1,243.32% | -1,128.88% | -532.81% | -228.79% | -190.22% | -287.32% | -118.80% | -68.42% | -6.11% |
| Operating Income | -12.56M | -13.67M | -14.32M | -6.62M | -6.01M | -5.27M | -3.92M | -1.06M | -627.39K | -71.71K |
| Operating Income Ratio | -1,409.33% | -1,323.38% | -1,207.70% | -626.02% | -261.27% | -215.93% | -317.17% | -119.86% | -69.53% | -7.43% |
| Total Other Income/Expenses | 671.36K | -235.03K | 300.44K | 81.04K | -91.17K | -187.87K | -33.93K | -4.17K | -159.31K | -37.69K |
| Income Before Tax | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Income Before Tax Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| Income Tax Expense | 0.00 | -211.26K | 1.00 | 100.77K | 508.00 | 465.85K | -18.62K | 0.00 | 0.00 | 0.00 |
| Net Income | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Net Income Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| EPS | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| Weighted Avg Shares Out | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.93K |
| Weighted Avg Shares Out (Dil) | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.92K |
Polarean Imaging chest coil receives FDA green light
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has received FDA 510(k) clearance for its XENOVIEW 3T chest coil to be used with GE HealthCare 3 Tesla (3T) MRI systems. The clearance allows the use of the device to support lung imaging using hyperpolarised Xenon-129...
Polarean Imaging's new sales VP explains his three-pronged strategy - ICYMI
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) new Vice President of Sales, Alan Huang explains his background and plans to boost revenue. Alan Huang: My background has primarily been in MedTech imaging solutions for radiology and radiation oncology departments.
Polarean Imaging raises its revenue target
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a specialist in MRI imaging of the lungs, said it is raising its revenue guidance for the year to $2.5 million to $3 million after a strong first half. It posted sales of $1.1 million in...
Polarean Imaging appoints Philips Healthcare veteran as sales vice president
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Alan Huang, formerly of Philips Healthcare, as the firm's new sales vice president. Having served at Philips for 12 years and as its MRI business units' North American head most recently, Huang joins...
Polarean Imaging appoints Xenon MRI specialist as its chief medical advisor
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Dr Chase Hall as chief medical advisor. An associate professor at the University of Kansas Medical Center, Hall specialises in pulmonary care and imaging biomarkers using Xenon MRI.
Polarean Imaging makes FDA supplemental submission to US FDA
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has submitted a New Drug Application supplement to the US Food & Drug Administration to allow XENOVIEW use in paediatric patients aged six years and older. The submission includes updates and new dose delivery bag sizes.
Polarean Imaging agrees trade-in deal with world-leading research centre
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) said it has agreed a trade-in deal with the University of Kansas Medical Center (KUMC) for a new clinical-grade Xenon MRI hyperpolariser system. KUMC, a leading academic centre in xenon MRI research, will exchange its existing...
Polarean trade-in puts it on track for clinical base target, says Stifel
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) trade-in agreement to exchange the University of Virginia Health System's (UVA Health) existing two research hyperpolarisers for two new clinical-grade systems is an encouraging development, Stifel suggests. Further conversion of existing research polarisers into clinical grade...
Polarean Imaging inks deal to upgrade UVA equipment
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) announced on Friday an agreement with the University of Virginia Health System, which sees the upgrade of its equipment. It involves trading UVA Health's existing two research hyperpolarisers for two clinical-grade hyperpolariser systems provided by...
Polarean Imaging focusing on its five pillars strategy
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) said the focus will be on executing its five pillars strategy after securing just under £10 million of new investment. So, in the current year, it will aim to drive the utilisation of its groundbreaking MRI...
Source: https://incomestatements.info
Category: Stock Reports